CMV IGG, IGG ANTIBODIES TO CYTOMEGALOVIRUS 04784596190

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a foreign,health professional,u report with the FDA on 2017-02-03 for CMV IGG, IGG ANTIBODIES TO CYTOMEGALOVIRUS 04784596190 manufactured by Roche Diagnostics.

Event Text Entries

[66507244] This event occurred in (b)(6). Unique identifier (udi)#: (b)(4).
Patient Sequence No: 1, Text Type: N, H10


[66507245] The customer stated that they have received an erroneous high result for one patient sample tested for the elecsys (b)(6) on a cobas 6000 e 601 module (e601). The erroneous result was reported outside of the laboratory. A first sample from the patient was tested on an e601 in the customer's laboratory on (b)(6) 2015 and resulted as 5. 7 u/ml ((b)(6)) for (b)(6). The result was obtained during the patient's first pregnancy and was not questioned. A second sample from the patient was tested in a second laboratory on an abbott architect analyzer on (b)(6) 2016, resulting as 0. 4 au/ml ((b)(6)) for (b)(6). A third sample from the patient was tested on the customer's e601 analyzer (serial number (b)(4)) on (b)(6) 2016 and the result was 27 u/ml ((b)(6)) for (b)(6). This sample was repeated at a third laboratory on an abbott architect analyzer on (b)(6) 2016, resulting as (b)(6) for (b)(6). The customer does not know if the patient is (b)(6) for (b)(6). The patient was not adversely affected.
Patient Sequence No: 1, Text Type: D, B5


[68620355] A sample from the patient was provided for investigation. Investigations were able to duplicate the results of the customer. The sample showed clear reactivity with the roche cmvigg assay. There was no evidence for systemic interference of the sample with the general assay components. Antigen specific interference also appeared to be unlikely. The presence of cmv specific igg antibodies is supported by the recomline cmv igg assay, however, the detected signals are below the assay's cutoff (borderline result). The cmv specific igg antibodies were determined to be of high avidity (101%). This suggests that the patient had been remotely infected with cmv and has already acquired specific immunity. The root cause of the observed discrepancy between the roche cmvigg assay and the abbott assay could not be determined. Further testing of the patient with other independent methods, together with information on the clinical history of the patient may help to refine the diagnostic cmv status.
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number1823260-2017-00213
MDR Report Key6300774
Report SourceFOREIGN,HEALTH PROFESSIONAL,U
Date Received2017-02-03
Date of Report2017-02-24
Date of Event2016-12-15
Date Mfgr Received2017-01-09
Date Added to Maude2017-02-03
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Reporter OccupationOTHER HEALTH CARE PROFESSIONAL
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactNA MICHAEL LESLIE
Manufacturer Street9115 HAGUE ROAD NA
Manufacturer CityINDIANAPOLIS IN 46250
Manufacturer CountryUS
Manufacturer Postal46250
Manufacturer Phone3175214343
Manufacturer G1ROCHE DIAGNOSTICS GMBH
Manufacturer StreetSANDHOFERSTRASSE 116 NA
Manufacturer CityMANNHEIM (BADEN-WURTTEMBERG) 68305
Manufacturer CountryGM
Manufacturer Postal Code68305
Single Use3
Previous Use Code3
Removal Correction NumberNA
Event Type3
Type of Report3

Device Details

Brand NameCMV IGG, IGG ANTIBODIES TO CYTOMEGALOVIRUS
Generic NameENZYME LINKED IMMUNOABSORBENT ASSAY, CYTOMEGALOVIRUS
Product CodeLFZ
Date Received2017-02-03
Model NumberNA
Catalog Number04784596190
Lot Number174473
ID NumberNA
Device Expiration Date2017-09-30
OperatorHEALTH PROFESSIONAL
Device AvailabilityY
Device AgeDA
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerROCHE DIAGNOSTICS
Manufacturer Address9115 HAGUE ROAD NA INDIANAPOLIS IN 462500457 US 462500457


Patients

Patient NumberTreatmentOutcomeDate
10 2017-02-03

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.